Published in Bioorg Med Chem Lett on April 19, 2004
Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob Agents Chemother (2008) 1.01
Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening. J Biomol Screen (2014) 1.00
4-[(3-Meth-oxy-anilino)methyl-idene]-2-phenyl-1,3-oxazol-5(4H)-one. Acta Crystallogr Sect E Struct Rep Online (2012) 0.83
Novel hybrid virtual screening protocol based on molecular docking and structure-based pharmacophore for discovery of methionyl-tRNA synthetase inhibitors as antibacterial agents. Int J Mol Sci (2013) 0.78
Evolutionary Limitation and Opportunities for Developing tRNA Synthetase Inhibitors with 5-Binding-Mode Classification. Life (Basel) (2015) 0.78
Essentiality Assessment of Cysteinyl and Lysyl-tRNA Synthetases of Mycobacterium smegmatis. PLoS One (2016) 0.76
A homology model for Clostridium difficile methionyl tRNA synthetase: active site analysis and docking interactions. J Mol Model (2010) 0.75
IA, database of known ligands of aminoacyl-tRNA synthetases. J Comput Aided Mol Des (2007) 0.75
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18
Classification of kinase inhibitors using a Bayesian model. J Med Chem (2004) 1.50
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem (2011) 1.45
Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother (2004) 1.13
Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem (2004) 1.03
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem (2006) 0.97
Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin. Bioorg Med Chem Lett (2003) 0.96
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. J Med Chem (2007) 0.96
Identification of a small molecule that induces mitotic arrest using a simplified high-content screening assay and data analysis method. J Biomol Screen (2005) 0.93
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med Chem (2007) 0.92
A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J Biol Chem (2011) 0.89
Control of chronic inflammation with pathway selective estrogen receptor ligands. Curr Top Med Chem (2006) 0.85
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem (2006) 0.84
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. Bioorg Med Chem Lett (2007) 0.83
Synthetic methods for the preparation of ARQ 501 (beta-Lapachone) human blood metabolites. Bioorg Med Chem (2008) 0.82
Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood. Drug Metab Dispos (2008) 0.82
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J Med Chem (2007) 0.82
A series of heterocyclic inhibitors of phenylalanyl-tRNA synthetases with antibacterial activity. Bioorg Med Chem Lett (2004) 0.82
High-content fluorescent-based assay for screening activators of DNA damage checkpoint pathways. J Biomol Screen (2008) 0.81
Array synthesis of novel lipodepsipeptide. Bioorg Med Chem Lett (2003) 0.80
Discovery of a potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors. Bioorg Med Chem Lett (2003) 0.79
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg Med Chem Lett (2004) 0.79
A series of spirocyclic analogues as potent inhibitors of bacterial phenylalanyl-tRNA synthetases. Bioorg Med Chem Lett (2004) 0.79
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Bioorg Med Chem Lett (2011) 0.78
N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR. Bioorg Med Chem Lett (2007) 0.77
In vitro metabolism of beta-lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Commun Mass Spectrom (2009) 0.76
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines. Bioorg Med Chem Lett (2002) 0.75
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines. Bioorg Med Chem Lett (2002) 0.75
Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett (2005) 0.75
Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica (2014) 0.75
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation. J Med Chem (2008) 0.75